This study demonstrates that TGR5 reduces macrophage-related inflammation and promotes macrophage M2 polarization in NASH by inhibiting NLRP3 activation, providing a theoretical basis for targeting TGR5/NLRP3 signaling for NASH treatment. Here, GPBAR1 is linked to metabolic dysfunction-associated steatohepatitis.